Enanta Pharmaceuticals (ENTA) investor relations material

Key clinical development insights

• Focused on RSV, the N-protein inhibitor program targets high-risk populations for maximum impact, emphasizing early intervention within days of symptom onset.

• Ongoing discussions with the FDA aim to define a first-of-its-kind registration path, with a public update expected by the end of Q2.

• Recent data show a week-long reduction in symptom resolution and a drop in RSV-related hospitalizations from 5% (placebo) to 0% (treatment group).

• Study endpoints under consideration include symptom improvement and hospitalization, balancing clinical relevance and trial efficiency.

• Fast Track designation has been granted for both RSV assets, and the regulatory agency has maintained a constructive stance.

Strategic and operational plans

• Multiple development pathways are being explored, including internal advancement and potential partnerships, especially for late-stage trials and commercialization.

• Preparations are underway to enable a new study launch later this year, including drug supply and protocol development.

• The team is leveraging payer and physician market research to inform endpoint selection and trial design.

• Combination approaches with L-protein and N-protein inhibitors are being considered, particularly for immunocompromised patients.

• Lifecycle management strategies include first establishing a market with the lead asset, then expanding with additional or combination therapies.

Scientific and mechanistic perspectives

• Allosteric and orthosteric STAT6 inhibitors are both considered viable, with the focus on achieving complete inhibition using potent small molecules.

• Preclinical models have demonstrated DUPIXENT-like activity with the STAT6 inhibitor in atopic dermatitis and asthma.

• Continuous drug exposure above target thresholds is emphasized for efficacy, with animal models already achieving high levels of target engagement.

• Drug distribution and plasma levels have met expectations in preclinical studies.

• The company’s experience in virology informs its approach to dosing and trial design for new indications.